Human Interleukin 33(IL-33) ELISA Kit

Code CSB-E13000h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
interleukin 33
Alternative Names
C9orf26 ELISA Kit; CHROMOSOME 9 OPEN READING FRAME 26 ELISA Kit; DKFZp586H0523 ELISA Kit; DVS27 ELISA Kit; DVS27 related protein ELISA Kit; IL 1F11 ELISA Kit; IL 33 ELISA Kit; IL-1F11 ELISA Kit; IL-33 ELISA Kit; IL1F11 ELISA Kit; IL33 ELISA Kit; IL33_HUMAN ELISA Kit; Interleukin 1 family member 11 ELISA Kit; Interleukin 33 ELISA Kit; INTERLEUKIN 33 NFHEV ELISA Kit; Interleukin 33 precursor ELISA Kit; Interleukin-1 family member 11 ELISA Kit; Interleukin-33 (109-270) ELISA Kit; Interleukin33 ELISA Kit; NF HEV ELISA Kit; NF-HEV ELISA Kit; NFEHEV ELISA Kit; NFHEV ELISA Kit; Nuclear factor for high endothelial venules ELISA Kit; Nuclear factor from high endothelial venules ELISA Kit; OTTHUMP00000021041 ELISA Kit; RP11 575C20.2 ELISA Kit
Abbreviation
IL33
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, urine
Detection Range
15.6 pg/mL-1000 pg/mL
Sensitivity
3.9 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human IL-33 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %89
Range %80-94
1:2Average %96
Range %90-99
1:4Average %106
Range %92-115
1:8Average %95
Range %86-100
Recovery
The recovery of human IL-33 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9589-99
EDTA plasma (n=4)9790-102
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
10001.894 1.752 1.823 1.728
5001.275 1.186 1.231 1.136
2500.734 0.698 0.716 0.621
1250.421 0.409 0.415 0.320
62.50.245 0.239 0.242 0.147
31.20.165 0.159 0.162 0.067
15.60.112 0.109 0.111 0.016
00.095 0.094 0.095  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The human IL-33 ELISA Kit is engineered for accurate measurement of human IL-33 levels from samples including serum, plasma, or urine. It uses the Sandwich-ELISA mechanism in combination with the enzyme-substrate chromogenic reaction to measure the IL-33 content in the sample. The color intensity is positively correlated with IL-33 content in the sample. The IL-33 concentration can be calculated according to the standard curve. This kit is tested with high sensitivity, strong specificity, good linearity, high precision and recovery, as well as lot-to-lot consistency.

IL-33 is constitutively expressed in the nucleus of epithelial, endothelial cells, and fibroblasts and participates in innate and adaptive immunity by enhancing Th2 cytokines generation. It is secreted secondary to cell apoptosis and necrosis. It functions as an 'alarmin' released following cell necrosis to alert the immune system to tissue damage or stress. IL-33 binds to a heterodimeric receptor ST2/IL-1R4 and forms a complex with the IL-1RAcP, recruiting the adaptor protein MyD88 and activating transcription factors such as NF-κB via TRAF6, IRAK-1/4, and MAP kinases and inducing the generation of inflammatory mediators. IL-33 drives the pathogenesis of Th2-related diseases such as asthma, atopic dermatitis, and anaphylaxis because it strongly induces Th2 cytokine production. However, IL-33 has shown various protective effects on cardiovascular diseases such as atherosclerosis, obesity, and type 2 diabetes.

Citations

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury.; In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets. This form is rapidely lost upon angiogenic or proinflammatory activation.
Gene References into Functions
  1. IL-33 has a role in the pathogenesis of autoimmune hepatitis (AIH) and affects the expression of IL-4, IL-17A, and of hypergammaglobulinemia PMID: 30034292
  2. The serum levels of IL-33 and IL-31 were significantly up-regulated in both AR and allergic asthma patients compared with normal individuals. PMID: 30301503
  3. chromatin binding is a post-translational mechanism that regulates the releasability and ST2-mediated bioactivity of IL-33. PMID: 30108214
  4. Results indicate that the interaction between FLIL33 and IPO5 is localized to a specific segment of the FLIL33 protein, is not required for nuclear localization of FLIL33, and protects FLIL33 from proteasome-dependent degradation. PMID: 29127199
  5. Data suggest that targeting interleukin 33 (IL-33) may be an effective treatment for sepsis-induced immunosuppression. PMID: 28374774
  6. Oxidative stress is involved in the expression of IL-33 in airway epithelial cells via MAPK signal pathway and IL-33 expression is augmented during viral infection. PMID: 29587772
  7. IL-33 expression plays an important role in patients with chronic rhinosinusitis with nasal polyp. PMID: 29186722
  8. IL-33(high) cholangiocarcinomas may represent a unique, less aggressive carcinogenetic process of the large bile ducts PMID: 29675965
  9. Our data suggest that IL-33 produced by M2 macrophages might contribute to the pathogenesis of IgG4-RD via aberrant activation of Th2 immune responses. PMID: 28205524
  10. The GLDC/IL33 locus on chromosome 9p24.1 as associated with overall survival in patients with osteosarcoma. PMID: 29210060
  11. Serum and sputum IL-33 levels were higher in chronic obstructive pulmonary disease subjects with sputum eosinophilia compared to those with a normal eosinophil count. PMID: 29859068
  12. Studies suggest that IL-33 acts as a possible pathogenic role in allergic diseases mainly by instructing the activation of various ST2-expressing cells and the production of several immune factors. The mechanisms underlying IL-33-mediated inflammation have been immunologically analyzed. However, much remains regarding the accurate functions and underlying mechanisms of the IL-33-ST2 signaling pathway. [review] PMID: 29987222
  13. Higher IL-33 and lower s-ST2 receptor baseline serum levels were detected in Pru p 3--sensitized allergic patients (SAP). IL-33/s-ST2 ratio is increased in Pru p 3-SAP and more in patients who experienced severe systemic symptoms. PMID: 29774370
  14. Strong immune reaction to herpes virus infection may depend on strong IL-33 expression in the epidermis, while very weak immune reaction in samples from patients with verruca vulgaris may be due to low or no expression of IL-33 in the lesional epidermis. PMID: 29696682
  15. data indicate that during acute, resolving colitis, IL-33/ST2 plays a crucial role in gut mucosal healing by inducing epithelial-derived miR-320 that promotes epithelial repair/restitution and the resolution of inflammation. PMID: 30224451
  16. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2. IL-33 functions via its receptor ST2 and upregulates COX2 expression through NF-kappaB signaling. Understanding the IL-33 signal transduction in colorectal cancer (CRC)cells provides potential therapeutic targets for clinical treatment PMID: 30119635
  17. Preincubation of LAD2 cells with the natural flavonoid methoxyluteolin (1-100 mM) inhibits (P < 0.0001) secretion and gene expression of IL-1beta, procaspase-1, and pro-IL-1beta. Mast cell secretion of IL-1beta in response to SP and IL-33 reveals targets for the development of antiinflammatory therapies. PMID: 30232261
  18. IL-33 could be suggested as a novel biomarker to distinguish different types of Salivary gland tumors PMID: 29991126
  19. IL-33 can regulate deposition of ECM and promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1. PMID: 29417309
  20. these data demonstrate the expression of IL33 in oral lichen planus lesions PMID: 29633015
  21. The aim of this study was to explore the possible correlations of serum interleukins and soluble ST2 (sST2) protein with clinical features and inflammatory cytokines in rheumatoid arthritis (RA) patients. PMID: 29798971
  22. IL-33 may down-regulate CLDN1 expression through the ERK/STAT3 pathway in keratinocytes. PMID: 29534857
  23. IL-33 promotes Renal Cell Carcinoma cell proliferation and chemotherapy resistance via its receptor ST2 and the JNK signaling activation in tumor cells. PMID: 29763892
  24. Low IL-33 expression is associated with experimental autoimmune encephalomyelitis susceptibility only in females. PMID: 29378942
  25. High IL33 expression is associated with schistosome infection. PMID: 29554131
  26. Serum IL-33 levels were significantly higher in patients with Behcet's disease compared to the healthy controls. PMID: 28412856
  27. In the present review, we have discussed the cellular sources, modes of action and regulation of IL-17 and IL-33 in the context of hypersensitive diseases [Review] PMID: 29153708
  28. results suggest that IL-33 acts as a cytokine but not as a nuclear factor regulating gene expression in endothelial cells PMID: 27694941
  29. IL-33 increased IL-10 expression in MFCs via activating ERK 1/2 and STAT3, which subsequently promoted IL-10 transcription and thus contributed to the beneficial effects of IL-33 on MFCs. PMID: 29099095
  30. IL-33 contributes to hepatic granuloma pathology through induction of M2 macrophages during S. japonicum infection. PMID: 27445267
  31. Serum levels of ST2, IL-33 and BNP were independent risk factors for major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. PMID: 28623858
  32. Recombinant human IL33 inhibited trophoblast invasion and adhesion, and decreased adhesion and invasionassociated molecules such as integrin alpha4beta1 and CD62L. PMID: 28765940
  33. TNF synthesis and secretion by mast cells is amplified by interactions of substance P and IL-33. PMID: 28461492
  34. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion PMID: 28668506
  35. Findings indicate that IL33 may be involved in the process of glioma cell invasion and migration by upregulating MMP2 and MMP9 via the ST2-NF-kappaB signaling pathway. PMID: 28849217
  36. IL-33 deficiency in mice does not lessen liver fibrosis during diet-induced steatohepatitis, in contrast to previous studies indicating a deleterious role of exogenous IL-33 in chronic liver injury and experimental NAFLD. PMID: 28611297
  37. The downregulation of epithelial IL-33 expression may potentially serve as a marker for disease remission in UC together with other biomarkers including mucosal TNF. PMID: 27748438
  38. Findings indicate that IL-10 act as a negative regulator of IL-33/ST2 signaling pathways in vivo. PMID: 28415811
  39. Study identify that IL-33 expression is reduced in many carcinomas upon their transition to the metastatic form of disease and, appears to be directly correlated with MHC-I and possibly co-regulated. These results suggest that the down-regulation of IL-33 takes place concomitantly with the transition from primary to metastatic tumors and represents an entirely new form of tumor immune-escape. PMID: 27619158
  40. The proinflammatory cytokine IL-33 induces differential tissue factor expression and activity in monocyte subsets, as well as the release of procoagulant microvesicless. In this manner, IL-33 may contribute to the formation of a prothrombotic state characteristic for cardiovascular disease. PMID: 28492698
  41. this review and meta-analysis showed that serum IL33 is a helpful biomarker for early diagnosis of childhood asthma PMID: 28410870
  42. IL-33 down-regulates the induction of hCAP-18/LL-37 production in human gingival epithelial cells. PMID: 28637951
  43. We found significantly higher serum IL-33 and soluble ST2 levels in patients with active adult-onset Still's disease. Results indicate that the IL-33/ST2 signaling pathway may play a role in the pathogenesis of the acute inflammation and skin manifestations associated with adult-onset Still's disease. PMID: 28365573
  44. IL-33 expression is associated with age and invasive depth of GC patients. PMID: 28000059
  45. serum levels elevated in both idiopathic granulomatous mastitis and breast cancer PMID: 27780363
  46. IL-33 induces IL-8 expression via JNK/c-Jun/AP-1 pathway in human vascular endothelial cells, and provides a new insight into the role of IL-33-induced IL-8 in the pathophysiology of atherosclerosis and vascular inflammation PMID: 29373608
  47. a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation PMID: 28013014
  48. The results of the present study indicate that ISTP may inhibit TARC/CCL17 production in human epidermal keratinocytes via the STAT1 signaling pathway and may be associated with the inhibition of IL33 production. PMID: 28447741
  49. Data suggest that interleukin-33 (IL-33) isoforms activate basophils and mast cells to drive type 2 inflammation in chronic stable asthma. PMID: 27432971
  50. Through induction of TF in vascular endothelial cells, IL-33 could enhance their thrombotic capacity and thereby might impact on thrombus formation in the setting of atherosclerosis. PMID: 27142573

Show More

Hide All

Subcellular Location
Nucleus. Chromosome. Cytoplasm. Cytoplasmic vesicle, secretory vesicle. Secreted.
Protein Families
IL-1 family
Tissue Specificity
Expressed at high level in high endothelial venules found in tonsils, Peyer patches and mesenteric lymph nodes. Almost undetectable in placenta.
Database Links

HGNC: 16028

OMIM: 608678

KEGG: hsa:90865

STRING: 9606.ENSP00000370842

UniGene: Hs.731660

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X